Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells

Biochemical and Biophysical Research Communications

Volumn 405, Issue 2, 2011, Pages 168-172

  Wu, Chun Chi ^a,b   Yu, Chang Tze Ricky ^c   Chang, Gee Chen ^d   Lai, Jin Mei ^e   Hsu, Shih Lan ^a,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHI NAN UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Aurora kinase; Drug resistance; Gefitinib; NF B; P53

Indexed keywords

AURORA A KINASE; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; WILD TYPE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; I-KAPPA B PROTEINS; LUNG NEOPLASMS; MUTATION; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79651474615     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.01.001     Document Type: Article

References (26)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., Thun M.J. Cancer statistics, 2004. CA Cancer J. Clin. 2004, 54:8-29.
2. Department of Health: Vital Statistics 2005, Department of Health, Taipei, 2005.
3. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J. Clin. 1999, 49:8-31.
4. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., Albain K.S., Cella D., Wolf M.K., Averbuch S.D., Ochs J.J., Kay A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
5. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
6. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
7. Metro G., Finocchiaro G., Toschi L., Bartolini S., Magrini E., Cancellieri A., Trisolini R., Castaldini L., Tallini G., Crino L., Cappuzzo F. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev. Recent Clin. Trials 2006, 1:1-13.
8. Ferrer-Soler L., Vazquez-Martin A., Brunet J., Menendez J.A., De Llorens R., Colomer R. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (review). Int. J. Mol. Med. 2007, 20:3-10.
9. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
10. Meulmeester E., Jochemsen A.G. P53: a guide to apoptosis. Curr. Cancer Drug Targets 2008, 8:87-97.
11. Rho J.K., Choi Y.J., Ryoo B.Y., Na I.I., Yang S.H., Kim C.H., Lee J.C. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 2007, 67:1163-1169.
12. Chang G.C., Yu C.T., Tsai C.H., Tsai J.R., Chen J.C., Wu C.C., Wu W.J., Hsu S.L. An epidermal growth factor inhibitor, gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. Eur. J. Pharmacol. 2008, 600:37-44.
13. Marumoto T., Zhang D., Saya H. Aurora-A-a guardian of poles. Nat. Rev. Cancer 2005, 5:42-50.
14. Gautschi O., Heighway J., Mack P.C., Purnell P.R., Lara P.N., Gandara D.R. Aurora kinases as anticancer drug targets. Clin. Cancer Res. 2008, 14:1639-1648.
15. Anand S., Penrhyn-Lowe S., Venkitaraman A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 2003, 3:51-62.
16. Briassouli P., Chan F., Savage K., Reis-Filho J.S., Linardopoulos S. Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res. 2007, 67:1689-1695.
17. Yang H., He L., Kruk P., Nicosia S.V., Cheng J.Q. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int. J. Cancer 2006, 119:2304-2312.
18. Meulmeester E., Pereg Y., Shiloh Y., Jochemsen A. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle (Georgetown, Tex.) 2005, 4:1166.
19. Thoreen C., Sabatini D. AMPK and p53 help cells through lean times. Cell Metab. 2005, 1:287-288.
20. Yang H., He L., Kruk P., Nicosia S., Cheng J. Aurora A induces cell survival and chemoresistance by activation of Akt through a p53 dependent manner in ovarian cancer cells. Int. J. Cancer 2006, 119:2304-2312.
21. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 2004, 36:55-62.
22. Liu Q., Kaneko S., Yang L., Feldman R.I., Nicosia S.V., Chen J., Cheng J.Q. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J. Biol. Chem. 2004, 279:52175-52182.
23. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262.
24. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
25. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., Novotny M., Slamon D.J., Plowman G.D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17:3052-3065.
26. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., Papadimitriou C.A., Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9:962-972.